Blueprint Medicines Corporation (BPMC) and Alector Inc. (NASDAQ:ALEC) Comparing side by side

Blueprint Medicines Corporation (NASDAQ:BPMC) and Alector Inc. (NASDAQ:ALEC), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Blueprint Medicines Corporation 44.30M 100.03 267.50M -5.39 0.00
Alector Inc. 28.36M 48.95 62.37M -0.76 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Blueprint Medicines Corporation and Alector Inc.

Net Margins Return on Equity Return on Assets
Blueprint Medicines Corporation -603.84% 0% 0%
Alector Inc. -219.92% 0% 0%

Liquidity

6.6 and 6.6 are the respective Current Ratio and a Quick Ratio of Blueprint Medicines Corporation. Its rival Alector Inc.’s Current and Quick Ratios are 6.1 and 6.1 respectively. Blueprint Medicines Corporation has a better chance of clearing its pay short and long-term debts than Alector Inc.

Analyst Ratings

The following table given below contains the ratings and recommendations for Blueprint Medicines Corporation and Alector Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Blueprint Medicines Corporation 0 0 2 3.00
Alector Inc. 0 0 2 3.00

Blueprint Medicines Corporation’s upside potential currently stands at 30.65% and an $118.5 consensus price target. Meanwhile, Alector Inc.’s consensus price target is $27, while its potential upside is 33.93%. Based on the data given earlier, Alector Inc. is looking more favorable than Blueprint Medicines Corporation, analysts view.

Institutional and Insider Ownership

The shares of both Blueprint Medicines Corporation and Alector Inc. are owned by institutional investors at 96% and 45.7% respectively. About 0.1% of Blueprint Medicines Corporation’s share are held by insiders. Comparatively, insiders own roughly 8.1% of Alector Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Blueprint Medicines Corporation 0.57% -0.64% 3.85% 28.2% -4.66% 43.2%
Alector Inc. 7.27% -11.58% 19.62% 0% 0% 21.28%

For the past year Blueprint Medicines Corporation’s stock price has bigger growth than Alector Inc.

Summary

Alector Inc. beats on 5 of the 9 factors Blueprint Medicines Corporation.

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing treatments that target cancer and rare genetic diseases. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.